Xenon’s Azetukalner Marks Success in Epilepsy Treatment
Company Announcements

Xenon’s Azetukalner Marks Success in Epilepsy Treatment

Story Highlights

Xenon (XENE) has released an update.

Xenon Pharmaceuticals Inc. presented compelling long-term data and reported quality of life improvements for adults with focal onset seizures at the 15th European Epilepsy Congress. Their drug, Azetukalner, shows more than a 90% reduction in seizure frequency in patients and has been linked to periods of seizure freedom lasting a year or longer.

For further insights into XENE stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks Canadian Auto-Generated NewsdeskXenon Advances Epilepsy and Depression Programs
TheFlyXenon Pharmaceuticals reports Q3 EPS (81c), consensus (81c)
Carrie WilliamsXENE Earnings this Week: How Will it Perform?
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App